See more : Weihai City Commercial Bank Co., Ltd. (9677.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Anika Therapeutics, Inc. (ANIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anika Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Lumos Diagnostics Holdings Limited (LDX.AX) Income Statement Analysis – Financial Results
- THG Plc (THGPF) Income Statement Analysis – Financial Results
- Helloworld Travel Limited (HLO.AX) Income Statement Analysis – Financial Results
- Pine Technology Acquisition Corp. (PTOCU) Income Statement Analysis – Financial Results
- Fat Projects Acquisition Corp (FATPW) Income Statement Analysis – Financial Results
Anika Therapeutics, Inc. (ANIK)
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M | 113.42M | 103.38M | 93.00M | 105.59M | 75.08M | 71.36M | 64.78M | 55.56M | 40.14M | 35.78M | 30.83M | 26.84M | 29.84M | 26.47M | 15.40M | 13.19M | 11.31M | 16.34M | 13.50M | 13.90M | 12.00M | 1.20M | 3.40M | 4.70M | 2.20M |
| Cost of Revenue | 63.57M | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M | 27.36M | 24.03M | 21.05M | 20.93M | 22.77M | 28.99M | 26.78M | 23.83M | 13.67M | 13.19M | 11.88M | 11.12M | 11.14M | 9.95M | 8.01M | 8.11M | 8.23M | 8.67M | 5.30M | 5.20M | 4.40M | 700.00K | 2.80M | 3.70M | 1.90M |
| Gross Profit | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M | 86.06M | 79.35M | 71.95M | 84.66M | 52.32M | 42.37M | 37.99M | 31.73M | 26.47M | 22.59M | 18.95M | 15.72M | 18.69M | 16.52M | 7.40M | 5.08M | 3.08M | 7.66M | 8.20M | 8.70M | 7.60M | 500.00K | 600.00K | 1.00M | 300.00K |
| Gross Profit Ratio | 61.85% | 59.89% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% | 63.14% | 61.46% | 58.58% | 62.65% | 62.41% | 48.03% | 38.51% | 27.26% | 46.91% | 60.74% | 62.59% | 63.33% | 41.67% | 17.65% | 21.28% | 13.64% |
| Research & Development | 32.69M | 28.18M | 27.33M | 23.43M | 16.67M | 18.19M | 18.79M | 10.73M | 8.99M | 8.14M | 7.06M | 5.39M | 6.17M | 6.87M | 8.18M | 7.40M | 4.36M | 3.62M | 4.73M | 4.09M | 2.60M | 3.93M | 4.28M | 3.26M | 4.20M | 2.00M | 2.00M | 0.00 | 1.30M | 1.50M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 0.00 | 900.00K | 700.00K | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.85M | 84.79M | 74.10M | 60.06M | 34.95M | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 2.60M | 900.00K | 700.00K | 1.90M |
| Other Expenses | 62.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54B | 0.00 | 0.00 | 2.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| Operating Expenses | 191.48M | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M | 40.33M | 28.75M | 23.81M | 23.22M | 20.00M | 20.12M | 24.03M | 24.19M | 18.73M | 18.36M | 12.36M | 10.30M | 10.14M | 10.13M | 6.80M | 8.35M | 10.49M | 8.65M | 8.30M | 5.50M | 4.40M | 3.20M | 2.50M | 2.40M | 2.20M |
| Cost & Expenses | 254.30M | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M | 67.69M | 52.77M | 44.87M | 44.15M | 42.76M | 49.11M | 50.81M | 48.02M | 32.40M | 31.55M | 24.24M | 21.41M | 21.28M | 20.08M | 14.81M | 16.46M | 18.72M | 17.32M | 13.60M | 10.70M | 8.80M | 3.90M | 5.30M | 6.10M | 4.10M |
| Interest Income | 0.00 | 654.00K | 188.00K | 498.00K | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.19K | 5.26M | 182.39K | 194.62K | 4.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.22M | 16.35M | 15.99M | 15.00M | 7.17M | 5.91M | 4.29M | 3.73M | 3.78M | 4.71M | 4.77M | 4.53M | 4.00M | 3.32M | 1.29M | 1.43M | 818.73K | 384.06K | 459.00K | 710.00K | 1.01M | 1.10M | 1.23M | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| EBITDA | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | 27.66M | 50.02M | 54.34M | 51.91M | 61.45M | 32.03M | 26.78M | 17.97M | 10.86M | 11.18M | 5.66M | 7.41M | 5.81M | 9.01M | 14.53M | 1.60M | -2.18M | -6.18M | 214.38K | 1.10M | 3.37M | 3.50M | -2.10M | -1.60M | -1.20M | -1.60M |
| EBITDA Ratio | -6.74% | -12.42% | -26.78% | -0.47% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 42.66% | 34.74% | 27.74% | 19.54% | 27.87% | 15.82% | 24.02% | 21.65% | 30.20% | 26.82% | 10.39% | -16.53% | -54.61% | 1.31% | 5.93% | 19.42% | 26.67% | -183.33% | -47.06% | -27.66% | -72.73% |
| Operating Income | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M | 45.73M | 50.61M | 48.13M | 61.45M | 32.61M | 19.72M | 13.97M | 7.54M | 5.59M | 4.23M | 6.59M | 5.43M | 8.55M | 6.39M | 595.00K | -3.27M | -7.41M | -983.37K | -100.00K | 3.20M | 3.20M | -2.70M | -1.90M | -1.40M | -1.90M |
| Operating Income Ratio | -52.58% | -12.42% | -12.50% | -11.09% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% | 11.81% | 21.37% | 20.22% | 28.66% | 24.14% | 3.86% | -24.83% | -65.51% | -6.02% | -0.74% | 23.02% | 26.67% | -225.00% | -55.88% | -29.79% | -86.36% |
| Total Other Income/Expenses | 2.31M | 654.00K | -188.00K | -302.00K | 1.87M | 1.46M | 473.00K | 263.00K | 120.00K | 58.14K | -127.00K | -187.78K | -182.39K | -194.62K | -2.23M | 498.51K | 2.10M | 2.10M | 1.24M | 388.71K | 144.00K | 239.00K | 662.19K | 1.17M | 1.38M | 700.00K | 200.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -85.33M | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M | 46.20M | 50.87M | 48.25M | 61.51M | 32.48M | 19.53M | 13.79M | 7.34M | 5.51M | 4.73M | 8.69M | 7.53M | 9.79M | 6.78M | 739.00K | -3.03M | -6.75M | 189.49K | -100.00K | 4.40M | 3.40M | -2.60M | 0.00 | -1.30M | -1.90M |
| Income Before Tax Ratio | -51.20% | -12.00% | 1.64% | -21.94% | 31.52% | 21.99% | 40.74% | 49.21% | 51.89% | 58.25% | 43.26% | 27.37% | 21.28% | 13.22% | 13.73% | 13.21% | 28.18% | 28.05% | 32.82% | 25.61% | 4.80% | -23.02% | -59.66% | 1.16% | -0.74% | 31.65% | 28.33% | -216.67% | 0.00% | -27.66% | -86.36% |
| Income Tax Expense | -2.66M | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M | 14.39M | 18.32M | 17.50M | 23.19M | 11.91M | 7.77M | 5.32M | 3.03M | 1.82M | 1.10M | 2.65M | 2.92M | 3.90M | -4.41M | -88.00K | 5.00K | 9.08K | 15.94K | 2.20M | 100.00K | 100.00K | -100.00K | 100.00K | -100.00K | -300.00K |
| Net Income | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M | 31.82M | 32.55M | 30.76M | 38.32M | 20.57M | 11.76M | 8.47M | 4.32M | 3.69M | 3.63M | 6.04M | 4.60M | 5.89M | 11.19M | 827.00K | -3.04M | -6.76M | 173.55K | -2.50M | 4.30M | 3.30M | -2.70M | -2.00M | -1.40M | -1.60M |
| Net Income Ratio | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% | 10.14% | 19.58% | 17.15% | 19.75% | 42.28% | 5.37% | -23.05% | -59.74% | 1.06% | -18.52% | 30.94% | 27.50% | -225.00% | -58.82% | -29.79% | -72.73% |
| EPS | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 | 0.34 | 0.32 | 0.32 | 0.55 | 0.43 | 0.57 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.26 | 0.38 | 0.60 | -0.56 | -0.61 | -0.45 | -0.51 |
| EPS Diluted | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 | 0.32 | 0.53 | 0.41 | 0.52 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.24 | 0.34 | 0.44 | -0.56 | -0.61 | -0.45 | -0.51 |
| Weighted Avg Shares Out | 14.66M | 14.56M | 14.40M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M | 12.62M | 11.39M | 11.31M | 11.06M | 10.64M | 10.41M | 11.42M | 9.95M | 9.93M | 9.93M | 9.87M | 9.74M | 9.89M | 5.00M | 4.82M | 3.28M | 3.11M | 3.14M |
| Weighted Avg Shares Out (Dil) | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M | 13.65M | 11.56M | 11.46M | 11.45M | 11.16M | 11.43M | 11.42M | 10.85M | 9.93M | 9.93M | 10.04M | 10.22M | 11.01M | 7.50M | 4.82M | 3.28M | 3.11M | 3.14M |
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair – is marketed in over 35 countries outside the U.S. where it has been clinically demonstrated to be safe and effective
High School Teams Earn National Honors in America’s Top Economics Competition
NEW YORK--(BUSINESS WIRE)--Showcasing mastery of the economic knowledge that helps young people achieve financial goals throughout their lives, student teams from Carmel High School of Carmel, Indiana, and Mt. Hebron High School of Ellicott City, Maryland, each earned first place...
Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript
Anika Therapeutics Inc. (NASDAQ:ANIK ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President, CEO & Director Michael Levitz - Executive VP,...
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.20 per share a year ago.
Anika Reports First Quarter 2023 Financial Results
Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11% Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2023 financial results after the close of...
Anika Enters Into Cooperation Agreement with Caligan Partners
Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee BEDFORD, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today...
Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20,...
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing
Anika Files Preliminary Proxy Statement
BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has filed its preliminary proxy materials with the Securities and...
Source: https://incomestatements.info
Category: Stock Reports